Dear Foregen Supporters,

Welcome back to our most recent newsletter. We have some important updates for you, and an overview of the best parts of March.

What's Happened Since Last Time?

  • Earlier last month we released a brief statement concerning COVID-19 and its impact on Foregen’s operations. At this time, our scientific operations and all activities within Italy remain completely suspended. We are in regular contact with our Italian colleagues, and are happy to report that they are currently doing well. Our administrative functions continue without interruption.
  • Our legal firm in Colombia has informed us that, unfortunately, at this time the current regulations do not allow for international donation or supply of tissues.
  • Our Chief Science Officer, Eric Cunningham, is continuing to compile numerous sources in order to bolster and refine his piece detailing the Bioethical issues involving circumcision and the use of neonatal tissue in Biotechnology, Biomedical research, and Cosmetics industries.
  • We are continuing communications with an international firm that can help us acquire the funding needed to support future phases of the project necessary for public release. We may have further details to share with you  about this relationship soon.
  • For the month of March we saw 187 new supporters sign up and reached a total of $8,436 in donations, which helps us move forward with the next parts of our mission!  Be sure to inform other activists, friends and family about Foregen and the science we’re pursuing to one day help provide genital integrity to men around the world. Our overall total to date is $582,107.83 Let’s keep it up.

Tell Me Something Interesting

  • This recent article about regenerative medicine and aging from Stanford Medicine provides details and insights into stem cells and induced pluripotent cells. “Induced pluripotent stem cells can become nearly any type of cell in the body, regardless of the cell from which they originated. They’ve become important in regenerative medicine and drug discovery.”

Thanks for reading, and stay tuned for our next newsletter. If you’d like more frequent updates, please head over to our blog, or visit one of our social media accounts – the links are in the website footer.

Stay safe everyone!


Matthew J. Serody

Senior Director